The role and assessment of morphological regression after neoadjuvant therapy in breast cancer patients
2015
Breast cancer neoadjuvant treatment response gives a unique opportunity to assess the therapy effectiveness only a few months after the therapy was initiated. In many neoadjuvant trials, patients achieving a pathologic complete response, showed a better long-term outcome, indicating pathologic complete response as a strong prognostic marker. However, there are some discrepancies in pathologic complete response assessment, thus standardization is needed. The review addresses the important issues regarding pathologic complete response assessment.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI